ALT vs. KRRO, KALV, FULC, NGNE, LRMR, ABUS, STTK, VERV, ATXS, and APLT
Should you be buying Altimmune stock or one of its competitors? The main competitors of Altimmune include Korro Bio (KRRO), KalVista Pharmaceuticals (KALV), Fulcrum Therapeutics (FULC), Neurogene (NGNE), Larimar Therapeutics (LRMR), Arbutus Biopharma (ABUS), Shattuck Labs (STTK), Verve Therapeutics (VERV), Astria Therapeutics (ATXS), and Applied Therapeutics (APLT). These companies are all part of the "pharmaceutical preparations" industry.
Altimmune (NASDAQ:ALT) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, community ranking, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.
Altimmune currently has a consensus price target of $15.00, suggesting a potential upside of 104.36%. Korro Bio has a consensus price target of $126.25, suggesting a potential upside of 137.85%. Given Korro Bio's stronger consensus rating and higher probable upside, analysts clearly believe Korro Bio is more favorable than Altimmune.
In the previous week, Altimmune had 12 more articles in the media than Korro Bio. MarketBeat recorded 12 mentions for Altimmune and 0 mentions for Korro Bio. Korro Bio's average media sentiment score of 1.05 beat Altimmune's score of 0.22 indicating that Korro Bio is being referred to more favorably in the news media.
Altimmune received 38 more outperform votes than Korro Bio when rated by MarketBeat users. However, 100.00% of users gave Korro Bio an outperform vote while only 69.12% of users gave Altimmune an outperform vote.
Altimmune has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, Korro Bio has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500.
78.1% of Altimmune shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 4.1% of Altimmune shares are held by company insiders. Comparatively, 16.8% of Korro Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Korro Bio has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.
Korro Bio has a net margin of 0.00% compared to Altimmune's net margin of -20,780.75%. Altimmune's return on equity of -44.77% beat Korro Bio's return on equity.
Summary
Korro Bio beats Altimmune on 11 of the 18 factors compared between the two stocks.
Get Altimmune News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Altimmune Competitors List
Related Companies and Tools
